Cytomegalovirus infections in allogenic stem cell recipients after reduced-intensity of myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia

Bone Marrow Transplantation

Volumn 32, Issue 7, 2003, Pages 695-701

  Schetelig, J ^a   Oswald, O ^a   Steuer, N ^a   Radonic, A ^a   Thulke, S ^a   Held, T K ^b   Oertel, J ^a   Nitsche, A ^a,c   Siegert, W ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Section of Pathology   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Allogeneic; Blood stem cell transplantation; Cytomegalovirus; Quantitative PCR; Reduced intensity

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA; ETOPOSIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; THIOTEPA; THYMOCYTE ANTIBODY; VIRUS ANTIGEN; ANTINEOPLASTIC AGENT; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; DOSE RESPONSE; METHODOLOGY; MIDDLE AGED; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROBABILITY; STANDARD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; PROBABILITY; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

EID: 0141962327     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704164     Document Type: Article

References (20)

1. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transplant Infect Dis 1999; 1: 165-178.
2. Nichols WG, Corey L, Gooley T et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-282.
3. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
4. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
5. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
6. Mohty M, Faucher C, Vey N et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26: 251-255.
7. Nitsche A, Steuer N, Schmidt CA et al. Different real-time PCR formats compared for the quantitative detection of human cytomegalovirus DNA. Clin Chem 1999; 45: 1932-1937.
8. Schetelig J, Kroger N, Held TK et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002; 87: 299-305.
9. Clift RA, Radich J, Appelbaum FR et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999; 94: 3960-3962.
10. Przepiorka D, Khouri I, Thall P et al. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 1999; 23: 977-981.
11. Schmidt CA, Oettle H, Peng R et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 1995; 59: 1133-1138.
12. Nitsche A, Steuer N, Schmidt CA et al. Detection of human cytomegalovirus DNA by real-time quantitative PCR. J Clin Microbiol 2000; 38: 2734-2737.
13. Bornhauser M, Thiede C, Platzbecker U et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001; 7: 2254-2262.
14. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867-874.
15. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
16. Faucher C, Mohty M, Chabannon C et al. Allogeneic transplantation with ATG base reduced intensity regimen and bone marrow (BM) graft is associated with rapid donor chimerism, low GVHD rate and rapid CD8+ T cells recovery. Bone Marrow Transplant 2002; 29 (Suppl 2): 157 (abstract 616).
17. Martino R, Caballero MD, Canals C et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341-347.
18. Bacigalupo A, Lamparelli T, Bruzzi P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
19. Perez-Simon JA, Kottaridis PD, Martino R et al. Non-myeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
20. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.